Weight-Loss Drugs Draw Americans Back to the Doctor
Weight-Loss Drugs May Lead to Earlier Diagnosis of Chronic Conditions
New data suggests GLP-1 medications could be prompting patients to seek more preventative care.
A groundbreaking analysis of electronic patient records reveals a potential silver lining to the surge in popularity of GLP-1 weight-loss drugs. While these medications, including Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Mounjaro and Zepbound, are known for their notable weight-loss results, new research suggests they may also be leading to earlier diagnoses of chronic conditions like type 2 diabetes, sleep apnea, and cardiovascular disease.
Health data firm Truveta analyzed hundreds of thousands of patient records and found slight but measurable increases in first-time diagnoses of these conditions within 15 days of an initial GLP-1 prescription between 2020 and 2024.
The analysis, which encompassed 33,630 first-time GLP-1 prescriptions in 2020 and a staggering 224,496 in the first 10 months of 2024, showed a notable trend. For every 1,000 patients starting GLP-1 treatment, the number of type 2 diabetes diagnoses within 15 days rose from 32 in 2020 to 42 in 2024. similarly, sleep apnea diagnoses increased from 8 to 11 per 1,000 patients, and cardiovascular disease diagnoses climbed from 13 to 15.
Experts are cautiously optimistic about these findings. Andrew Friedson, director of health economics at the Milken Institute, acknowledges that the long-term impact of these drugs on overall healthcare use remains unclear.
“The new diagnoses could mean higher initial spending,” Friedson explains, “but early detection could save costs down the line.”
Dr.Courtney Younglove,an obesity medicine specialist in Overland park,Kansas,has witnessed this phenomenon firsthand. She notes that many overweight patients avoid routine medical care due to stigma and bias.“A lot of people with obesity don’t do a lot of preventive health maintenance,” Younglove says.
She has observed that GLP-1 prescriptions ofen encourage patients to seek long-delayed screenings, including pap smears, colonoscopies, and other essential tests.
Phil, a 43-year-old Chicago technology executive, exemplifies this trend.He avoided doctors for years before starting a GLP-1 medication through a telehealth provider in early 2023. After losing over 30 pounds, he finally informed his primary care physician about the medication.“It gave me the courage to ask,” Phil shared, explaining that his doctor’s supportive response emboldened him to address other health concerns, including addiction and mental health.
The Truveta data also revealed that the most obese patients were twice as likely to receive a type 2 diabetes diagnosis and three times as likely to be diagnosed with sleep apnea compared to less overweight individuals.
While both Novo Nordisk and Eli Lilly declined to directly comment on the Truveta analysis, they emphasized their commitment to providing appropriate care for individuals living with obesity.
This emerging trend highlights the potential for GLP-1 medications to not only promote weight loss but also encourage proactive healthcare engagement, leading to earlier detection and perhaps better long-term health outcomes.
Weight-Loss Drugs: A Potential Gateway to Earlier Chronic Condition Diagnosis?
NewsDirectory3.com – A groundbreaking analysis of electronic patient records suggests that GLP-1 weight-loss drugs,like Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Mounjaro and Zepbound,could be prompting individuals to seek more preventative care,leading to earlier diagnoses of chronic conditions.
Health data firm Truveta analyzed hundreds of thousands of patient records and found slight but measurable increases in first-time diagnoses of type 2 diabetes, sleep apnea, and cardiovascular disease within 15 days of an initial GLP-1 prescription between 2020 and 2024.This trend was observed across a vast increase in GLP-1 prescription numbers,jumping from 33,630 in 2020 to a staggering 224,496 in the first 10 months of 2024.
While experts are cautious about attributing these findings solely to GLP-1 medications, they acknowledge the potential benefits.Andrew Friedson, director of health economics at the Milken Institute, suggests that while initial healthcare spending might increase due to new diagnoses, early detection could lead to cost savings in the long run.
Dr. Courtney Younglove, an obesity medicine specialist, has seen this firsthand. she notes that many overweight individuals avoid routine medical care due to stigma and bias.GLP-1 prescriptions, she says, frequently enough encourage these patients to finally seek long-delayed screenings.
Phil,a 43-year-old Chicago technology executive,exemplifies this trend.
Avoiding doctors for years, he began a GLP-1 medication through a telehealth provider in early 2023. After losing over 30 pounds, he finally informed his primary care physician about the medication. This led him to address other health concerns, including addiction and mental health.
The Truveta data also revealed that the most obese patients were twice as likely to receive a type 2 diabetes diagnosis and three times as likely to be diagnosed with sleep apnea compared to less overweight individuals.
Both Novo Nordisk and Eli Lilly declined to comment on the Truveta analysis but emphasized their dedication to providing appropriate care for individuals living with obesity.
This emerging trend highlights the potential for GLP-1 medications to not only promote weight loss but also encourage proactive healthcare engagement, leading to earlier detection and potentially better long-term health outcomes.